GSK778 hydrochloride
CAS No. 2863657-79-6
GSK778 hydrochloride( —— )
Catalog No. M37654 CAS No. 2863657-79-6
GSK778 hydrochloride hydrochloride is a potent and selective BD1 bromodomain inhibitor of the BET proteins, with IC50s of 75 nM (BRD2 BD1), 41 nM (BRD3 BD1), 41 nM (BRD4 BD1), and 143 nM (BRDT BD1), respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 319 | In Stock |
|
| 5MG | 249 | In Stock |
|
| 10MG | 368 | In Stock |
|
| 25MG | 562 | In Stock |
|
| 50MG | 770 | In Stock |
|
| 100MG | 1032 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGSK778 hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK778 hydrochloride hydrochloride is a potent and selective BD1 bromodomain inhibitor of the BET proteins, with IC50s of 75 nM (BRD2 BD1), 41 nM (BRD3 BD1), 41 nM (BRD4 BD1), and 143 nM (BRDT BD1), respectively.
-
DescriptionGSK778 hydrochloride hydrochloride is a potent and selective BD1 bromodomain inhibitor of the BET proteins, with IC50s of 75 nM (BRD2 BD1), 41 nM (BRD3 BD1), 41 nM (BRD4 BD1), and 143 nM (BRDT BD1), respectively. GSK778 hydrochloride hydrochloride phenocopies the effects of pan-BET inhibitors in cancer models.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorEpigenetic Reader Domain
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2863657-79-6
-
Formula Weight548.08
-
Molecular FormulaC30H34ClN5O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC[C@@H](N1C(COC)=NC2=C1C3=CC(OC[C@@H]4CNCC4)=C(C5=C(C)ON=C5C)C=C3N=C2)C6=CC=CC=C6.[H]Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Y06036
Y06036 a potent and selective BET inhibitor can bind to the BRD4(1) bromodomain (Kd: 82 nM).
-
IRAK4-IN-1
IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC50 of 7 nM.
-
FHT-1015
FHT-1015 is a potent SMARCA4/SMARCA2 ATPase (BRG1 and BRM) inhibitor with potential anticancer activity for the study of cancer and inflammation.
Cart
sales@molnova.com